IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants — RACHI_dex  

Spinal Anesthesia Clinical Trial

Official title: IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants : RACHI_dex

Status Recruiting

Clinical Trial Summary

- Spinal anesthesia in newborns is one of " Gold standard " techniques in short subumbilical surgeries (less than 30 minutes) with advantage of avoiding the risks inherent to general anesthesia. - Spinal anesthesia of the newborn remains a complex technical procedure with a failure rate of up to 16%. The child's movements and certain degrees of discomfort may also interfere with the successful completion of the procedure. - The second major issue of spinal anesthesia is the limitation of the motor block duration and the need for general anesthesia to complete the surgery - Spinal anesthesia duration can be prolonged by the addition of differents adjuvant such as opioid or alpha 2 adrenergic agonist. - Since 2018, dexmedetomidine, an alpha 2 adrenergic agonist with sedative, analgesic and anxiolytic properties, is being used as a current and standard practice in our anesthesia department. Intravenous administrationis performed ten to twenty minutes before spinal anesthesia placement in all children weighing less than 7 kg undergoing an infra-umbilical surgery of expected duration of less than 1 hour. This strategy ensures the child's comfort and allows the procedure to be performed under optimal conditions for practitionner. - The objective of this study is to review our practices and to evaluate the impact of the use of dexmedetomidine during spinal anesthesia of newborns and infants.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Infant
• Newborns
• Spinal Anesthesia

• NCT number: NCT04598061
• Study type: Observational
• Source: University Hospital, Montpellier
• Contact: Chrystelle SOLA, PH
• Phone: 06 65 84 91 66
• Email: c-sola@chu-montpellier.fr
• Status: Recruiting
• Start date: October 1, 2020
• Completion date: November 28, 2023